首页> 外文期刊>ChemMedChem >Computational Insight into p21-Activated Kinase 4 Inhibition: A Combined Ligand- and Structure-Based Approach
【24h】

Computational Insight into p21-Activated Kinase 4 Inhibition: A Combined Ligand- and Structure-Based Approach

机译:p21激活的激酶4抑制的计算见解:基于配体和结构的组合方法

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

p21-Activated kinase 4 (PAK4) is a serine/threonine protein kinase that plays important roles in a wide variety of human diseases including cancer. Targeting this kinase with specific inhibitors is of great interest in the treatment of cancer. In this study, PAK4 and its interaction with ATP-competitive inhibitors was investigated by a combined ligand- and structure-based approach. First, a ligand-based pharmacophore model was generated, consisting of five chemical features: a positive ion-izable center, two hydrophobic groups, a hydrogen bond donor, and a hydrogen bond acceptor, which is consistent with available SAR information. The characteristics of the active site were then described as a topological region and used in docking of nine selected inhibitors. Combination of the pharmacophore model and results from the docking studies allowed us to weigh the various pharmacophore features and to identify the positive ionizable center as a spacer rather than an essential point. This research led to the proposal of an interaction model inside the PAK4 active site and provided guidance for the design of more potent PAK4 inhibitors.
机译:p21激活激酶4(PAK4)是一种丝氨酸/苏氨酸蛋白激酶,在包括癌症在内的各种人类疾病中发挥着重要作用。用特异性抑制剂靶向该激酶在癌症的治疗中引起了极大的兴趣。在这项研究中,PAK4及其与ATP竞争性抑制剂的相互作用通过基于配体和结构的组合方法进行了研究。首先,生成了基于配体的药效团模型,该模型由五个化学特征组成:可阳离子化的中心,两个疏水基团,氢键供体和氢键受体,与可用的SAR信息一致。然后将活性位点的特征描述为一个拓扑区域,并用于对接九种选定的抑制剂。药效基团模型与对接研究的结果相结合,使我们能够权衡各种药效基团特征,并确定可电离的正离子中心是一个隔离子,而不是关键点。这项研究提出了在PAK4活性位点内部建立相互作用模型的建议,并为设计更有效的PAK4抑制剂提供了指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号